Russia’s Sputnik V vaccine 91.6% efficient towards COVID-19 in late-stage trial: research

Russia’s Sputnik V vaccine was 91.6% efficient towards COVID-19 illness in a late-stage trial, in line with new interim outcomes. The outcomes are available stark distinction to messaging from U.S. well being officers, together with Dr. Anthony Fauci, who sowed critical doubt over the jab after it was rolled out in Russia forward of superior research on security and efficacy.

The findings, printed in The Lancet on Tuesday, drew from a double-blind trial throughout 25 websites in Moscow, and revealed a 91.6% efficacy towards COVID-19 illness 21 days after the primary dose, and 100% effectiveness towards moderate-to-severe COVID-19 illness amongst some 19,800 grownup individuals. 

“Our interim evaluation of this part 3 trial of Gam-COVID-Vac has proven promising outcomes,” research authors wrote, later writing, “Our interim evaluation of the randomised, managed, part 3 trial of Gam-COVID-Vac in Russia has proven excessive efficacy, immunogenicity, and a superb tolerability profile in individuals aged 18 years or older.” 

Study co-leads included Denis Logunov and Dr. Inna Dolzhikova, who’re affiliated with The Gamaleya Center in Moscow.

The group of Russian researchers derived vaccine efficacy outcomes from 78 instances of COVID-19 that cropped up amongst all trial individuals three weeks after the primary dose.


“From 21 days after the primary dose of vaccine (the day of dose 2), 16 (0.1%) of 14,964 individuals within the vaccine group and 62 (1.3%) of 4,902 within the placebo group had been confirmed to have COVID-19; vaccine efficacy was 91.6%,” research authors wrote. 

After no less than 21 days from the preliminary dose, there have been no instances of moderate-to-severe COVID-19 within the vaccine group, however 20 instances arose within the placebo group, translating to 100% vaccine efficacy towards extra critical programs of illness.

Researchers urged the two-dose recombinant adenovirus vaccine induced an immune response, together with amongst older adults, and was properly tolerated; 45 (0.3%) of 16,427 vaccinated individuals and 23 (0.4%) of 5,435 folks given the placebo had critical hostile occasions, however these critical unwanted side effects weren’t thought of vaccine-related.


The most typical unwanted side effects had been “flu-like sickness, injection website reactions, headache” and weak point, per the research.

There had been additionally 4 deaths reported amongst trial individuals, (three within the vaccine group) however none had been discovered to be related to the vaccine. Among the vaccine group, two deaths had been tied to COVID-19; “these two individuals had been in all probability already contaminated with SARS-CoV-2 on the time of randomisation and vaccination,” research authors wrote. The different loss of life concerned a backbone fracture. The loss of life within the placebo group concerned a hemorrhagic stroke.

Several unknowns stay, like period of safety, and the way properly the vaccine works in youngsters, kids and pregnant girls.

Of notice, the sweeping majority of trial individuals had been white, and the Russian researchers mentioned they “welcome additional investigation in a extra numerous cohort.”

Finally, the group famous that, as of Jan. 23, over 2 million doses of the Sputnik V vaccine have already been administered to the general public in Russia, principally in high-risk populations, and important staff like well being care personnel and educators. 


“The part 1/2 medical trials of the vaccine had been accomplished in August, 2020,” research authors wrote. “The outcomes confirmed that the vaccine was properly tolerated and extremely immunogenic in wholesome individuals. As a end result, the vaccine candidate was provisionally accredited in Russia in line with nationwide laws.”

Researchers are additionally wanting right into a single-dose routine of the vaccine.

The vaccine efficacy outcomes exceed these just lately introduced by Johnson & Johnson, which noticed its single-shot coronavirus vaccine reveal 66% efficacy in stopping moderate-to-severe COVID-19 in a worldwide trial. However, mRNA vaccines developed by Pfizer-BioNTech and Moderna are 95% and 94.5% efficient towards COVID-19 illness, respectively.

Source hyperlink

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles